Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Lineage Cell Therapeutics Inc., 3 years.
Lineage Cell Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | STAAR Surgical Company | Option exercise | +5,233 | — | — |
| Aug 14, 2026 | STAAR Surgical Company | Shares withheld for tax | −2,662 | $26.18 | $69,691 |
| Jul 31, 2026 | STAAR Surgical Company | Option exercise | +20,787 | — | — |
| Jul 31, 2026 | STAAR Surgical Company | Shares withheld for tax | −10,576 | $24.36 | $257,631 |
| Jun 25, 2026 | STAAR Surgical Company | Option exercise | +13,955 | — | — |
| Jun 25, 2026 | STAAR Surgical Company | Shares withheld for tax | −6,480 | $31.21 | $202,241 |
| May 15, 2026 | STAAR Surgical Company | Grant or award | +10,466 | — | — |
| May 15, 2026 | STAAR Surgical Company | Shares withheld for tax | −3,755 | $32.07 | $120,423 |
| May 15, 2026 | STAAR Surgical Company | Grant or award | +5,233 | — | — |
| May 15, 2026 | STAAR Surgical Company | Shares withheld for tax | −1,877 | $32.07 | $60,195 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.